Merck & Company Inc (MRK)vsRigel Pharmaceuticals Inc (RIGL)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
RIGL
Rigel Pharmaceuticals Inc
$29.93
-1.06%
HEALTHCARE · Cap: $593.55M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 21840% more annual revenue ($65.77B vs $299.77M). RIGL leads profitability with a 121.5% profit margin vs 13.6%. RIGL trades at a lower P/E of 1.7x. RIGL earns a higher WallStSmart Score of 65/100 (B-).
MRK
Hold50
out of 100
Grade: D+
RIGL
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
+87.7%
Fair Value
$283.28
Current Price
$29.93
$253.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 91 in profit
Keeps 122 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 20.2%
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Smaller company, higher risk/reward
Earnings declined 30.2%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 121.5% and operating margin at 20.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while RIGL is a mature play — different risk/reward profiles.
RIGL carries more volatility with a beta of 1.18 — expect wider price swings.
RIGL is growing revenue faster at 10.3% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
RIGL scores higher overall (65/100 vs 50/100), backed by strong 121.5% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?